Q-omics provides the consensus-scored RYK profile across patient tissues and cancer cell-line models. RYK expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, RYK is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RYK RNA expression shows 20,665 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight PAAD, HNSC, and KIRP as cancer lineages where RYK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RYK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RYK survival associations across molecular data types. RYK RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RYK RNA expression–survival associations across cancer types. High RYK expression shows unfavorable associations in PAAD, LIHC, LGG, KICH and ACC, but favorable associations in KIRC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify PAAD as the clearest survival context for RYK RNA expression.
This table summarizes RYK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RYK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RYK shows lower tumor expression in BRCA and KICH and higher tumor expression in HNSC, LIHC, COAD and CHOL. The HNSC box plot shows higher RYK RNA expression in tumor versus normal tissue (log2 FC = +0.805, t-test p < 0.001).
This table shows molecular features associated with RYK in patient tissues and cancer cell lines. In patient samples, RYK shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RYK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
